Moderna (MRNA) Surpasses Estimates with $678M Revenue, Reiterates 10% 2026 Revenue Growth

Moderna (MRNA) reported fourth-quarter revenue of $678 million, exceeding the $626.1 million average estimate and analyst expectations. The result reflects stronger-than-anticipated sales of its COVID-19 vaccine in the U.S., supporting the company's pivot to newer products as demand for the vaccine waned post-pandemic. The company reiterated a 10% revenue growth outlook for 2026, citing continued momentum in mRNA technology and its broader pipeline. Data source: LSEG.